Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,768 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.
Zhang J, Tsai TF, Lee MG, Zheng M, Wang G, Jin H, Gu J, Li R, Liu Q, Chen J, Tu C, Qi C, Zhu H, Ports WC, Crook T. Zhang J, et al. Among authors: lee mg. J Dermatol Sci. 2017 Oct;88(1):36-45. doi: 10.1016/j.jdermsci.2017.05.004. Epub 2017 May 16. J Dermatol Sci. 2017. PMID: 28558978 Free article. Clinical Trial.
Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
Lee MG, Huang YH, Lee JH, Lee SC, Kim TG, Aw DC, Bao W, Dee CMA, Guana A, Tsai TF. Lee MG, et al. Among authors: lee jh, lee sc. J Dermatol. 2019 Sep;46(9):752-758. doi: 10.1111/1346-8138.15004. Epub 2019 Jul 25. J Dermatol. 2019. PMID: 31342560 Clinical Trial.
Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: post-hoc analysis from the phase III, double-blind, placebo- and active-comparator-controlled VOYAGE 1/2 trials.
Youn SW, Yu DY, Kim TY, Kim BS, Lee SC, Lee JH, Choe YB, Lee JH, Choi JH, Roh JY, Jo SJ, Lee ES, Shin MK, Lee MG, Jiang J, Lee Y. Youn SW, et al. Among authors: lee y, lee mg, lee jh, lee es, lee sc. J Dermatolog Treat. 2022 Feb;33(1):535-541. doi: 10.1080/09546634.2020.1770174. Epub 2020 May 27. J Dermatolog Treat. 2022. PMID: 32419536 Free article. Clinical Trial.
1,768 results